ACE and COVID-19: Patients with severe COVID-19 and diabetes or hypertension as comorbidities were advised not be treated with ACE inhibitors or angiotensin IIAT1 receptor inhibitors because a potential upregulation of ACE2 would facilitate and worsen SARS-CoV-2 infection (Fang et al., 2020; Wan et al., 2020).